AMANDA BOWMAN: Open Payments
NPI 1053841254 · BEDFORD, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 27 payments from 12 companies in 2025. Trend: 2023 $139 · 2024 $397 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $94 |
| ABBVIE INC. | 4 | $85 |
| Novo Nordisk Inc | 4 | $62 |
| Exact Sciences Corporation | 3 | $57 |
| Amgen Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: CAPLYTA, VRAYLAR, Ozempic, The Cologuard Plus Collection Kit, OTEZLA, Auvelity, REXULTI, JARDIANCE.
Industry payments across IN — which companies pay providers there.
